Anavex Life Sciences Corp.AVXLNASDAQ
Loading
| Metric | Sep 21 | Sep 22 | Sep 23 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Income | -42 | -51 | -56 |
| Net Income | -38 | -48 | -48 |
| EBITDA | -38 | -48 | -47 |
| EPS Diluted | -0.54 | -0.62 | -0.60 |
| Metric | Sep 21 | Sep 22 | Sep 23 |
|---|---|---|---|
| Cash & Equivalents | 152 | 149 | 151 |
| Total Current Assets | 162 | 153 | 154 |
| Total Assets | 162 | 153 | 154 |
| Total Current Liabilities | 11 | 10 | 13 |
| Total Liabilities | 11 | 10 | 13 |
| Total Equity | 151 | 142 | 142 |
| Total Debt | 0 | 0 | 0 |
| Net Debt | -152 | -149 | -151 |
| Metric | Sep 21 | Sep 22 | Sep 23 |
|---|---|---|---|
| Operating Cash Flow | -30 | -24 | -28 |
| Capital Expenditure | 0 | 0 | 0 |
| Free Cash Flow | -30 | -24 | -28 |
| Stock-Based Comp | 8 | 18 | 16 |
| Net Change in Cash | 123 | -3 | 2 |